Phase I/II study of adoptive immunotherapy comprising pyrophosphomonoester antigen-stimulated T cells, IL-2, and nitrogen-containing bisphosphonates in patients with stage IV renal cell carcinoma.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Aldesleukin (Primary) ; Zoledronic acid (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- 10 Jul 2013 Biomarkers information updated
- 21 Aug 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 08 Feb 2008 New trial record.